Investigation of Intestinal Enzyme Activity and Effects of Non-starch Polysaccharide on it

  • Abstract
  • Keywords
  • References
  • PDF
  • Abstract

    Background and Purpose: Shigella is a human shigellosis and its lipopolysaccharide is identified by 4TLR. The 4TLR is a family of pseudo-TOLL receptors and many immune routes are triggered by stimulating these receptors. Many studies show increasing of 4TLR expression in Mesenchyme stem cells under the influence of lipopolysaccharide. The main objective of this study was to identify the appropriate lipopolysaccharide of Shigella strains by stimulating the immune system for vaccine studies. Materials and Methods: In this experimental study, the stem cell of human Mesenchymal derived from bone marrow was treated by three dilution of 0.1, 0.01, and 0.001 extract of Shigella strains (Flexneri, Dysentery and Sonnei) containing lipopolysaccharide. Then, the expression of 4TLR at RNA level was evaluated by RT-PCR and Q-PCR techniques. Cells treated with phosphate buffer saline were considered as control group. Findings: The expression of 4TLR was observed in all treatments groups except for treatment groups with relative concentration of 0.001 sonnei and dysentery as well as control group. Changes in 4TLR expression were dose-dependent on all treatment groups. The highest expression was related to the treatment with Shigella Flexneri extract and the smallest was related to Shigella sonnei. The use of pure lipopolysaccharide of Escherichia coli as a positive control showed that the lipopolysaccharide in Shigella extract is responsible for increasing the expression of 4TLR. Conclusion: given the increased expression of 4TLR by Shigella extract, this extract is recommended to increase the efficacy of the vaccine.


  • Keywords

    Cell Extracts, Laboratory Conditions, Intrinsic Immunity, Lipopolysaccharide, Shigella.

  • References

      [1] Nhung PH, Ohkusu K, Mishima N, Noda M, Shah MM, Sun X, Phylogeny and species identification of the family Enterobacteriaceae based on dnaJ sequences. Diagnostic microbiology and infectious disease. 2007; 58(2): 153-61.

      [2] Key B, Clemens J, Kotloff K. Generic Protocol to Estimate the Burden of Shigella Diarrhoea and Dysenteric Mortal, Tex. Book; 1999.P. 146-51.

      [3] 3. Brooks G. Mycoplasmas & cell wall-defective bacteria. U: Brooks GF, Carroll KC, Butel JS. Morsa SA, Mietzner TA, ur. Jawetz, Melnick & Adelberg’s Medical Microbiology. New York: McGraw-Hill Companies, Inc; 2010.

      [4] Man AL, Prieto-Garcia ME, Nicoletti C. Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys? Immunology. 2004;113(1):15-22.

      [5] Trent MS, Stead CM, Tran AX, Hankins JV. Invited review: diversity of endotoxin and its impact on pathogenesis. Journal of endotoxin research. 2006; 12(4):205-23.

      [6] 6. Rallabhandi P, Awomoyi A, Thomas KE, Phalipon A, Fujimoto Y, Fukase K, et al. Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: combined effects of lipid A acylation state and TLR4 polymorphisms on signaling. The Journal of Immunology. 2008; 180(2):1139-47.

      [7] 7. Aboussahoud W, Aflatoonian R, Bruce C, Elliott S, Ward J, Newton S, et al. Expression of Toll-like Receptors in Human EndometrialEpithelial Cells and Cell Lines. Journal of Reproductive Immunology. 2010; 84(1): 41-51.

      [8] 8. Aflatoonian R, Tuckerman E, Elliott S, Bruce C, Aflatoonian A, Li T, Menstrual cycledependent changes of Toll-like receptors in endometrium. Human Reproduction. 2007; 22(2): 586-93.

      [9] 9. Miyake K, editor. Innate immune sensing of pathogens and danger signals by cell surface Tolllike receptors. Seminars in immunology; 2007; 19: 3- 10.

      [10] 10. Hwa Cho H, Bae YC, Jung JS. Role of Toll- Like Receptors on Human Adipose-Derived Stromal Cells. Stem Cells. 2006;24(12):2744-52.

      [11] 11. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783-801.

      [12] 12. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB. Toll-Like Receptors on Human Mesenchymal Stem Cells Drive Their Migration and Immunomodulating Responses. Stem Cells. 2008;26(1): 99-107.

      [13] DelaRosa O, Lombardo E. Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. Mediators of inflammation. 2010;2010.p. 865601-2.

      [14] 14. Bäckhed F, Normark S, Schweda EK, Oscarson S, Richter-Dahlfors A. Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications. Microbes and infection. 2003; 5(12):1057-63.

      [15] Jahantigh D, Saadati M, Ramandi MF, Mousavi M, Zand A. Novel Intranasal Vaccine Delivery System by Chitosan Nanofibrous Membrane Containing N-Terminal Region of Ipad Antigen as a Nasal Shigellosis Vaccine, Studies in Guinea Pigs. Journal of Drug Delivery Science and Technology. 2014;24(1):33-9.

      [16] Saadati M, Heiat M, Nazarian S, Barati B, Honari H, Doroudian M, et al. Cloning and Expression of N-terminal Region of IpaD from Shigella dysenteriae in E. coli. Journal of Paramedical Sciences. 2010;1(4):12-7.

      [17] 17. Mallaei F, Saadati M, Honari H, Nazariyan Sh, Eghtedardoust M, Heiat M, et al. Cloning and expression of ipaC gene from Shigella dysenteriae. Kowsar Medical Journal 2011; 16: 1-6.

      [18] 18. Emadedin M, Aghdami N, Taghiyar L, Fazeli R, Moghadasali R, Jahangir S, et al. Intraarticular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. Archives of Iranian medicine. 2012(15):422-8.

      [19] 19. Shi L, Wang J-S, Liu X-M, Hu X-Y, Fang Q. Upregulated functional expression of Toll like receptor 4 in mesenchymal stem cells induced by lipopolysaccharide. Chinese medical journal. 2007;120(19):1685-8.

      [20] 20. Lin H, Xu R, Zhang Z, Chen L, Shi M, Wang F-S. Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases. Cellular & molecular immunology. 2011;8(1):19-22.

      [21] 21. Tyndall A. Mesenchymal stem cell treatments in rheumatology [mdash] a glass half full? Nature Reviews Rheumatology. 2014;10(2):117-24.

      [22] 22. DelaRosa O, Dalemans W, Lombardo E. Tolllike receptors as modulators of mesenchymal stem cells. Frontiers in immunology. 2012;3:182.

      [23] 23. Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov A, Cohen S, et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood. 2007;109(4): 1422-32.

      [24] 24. Loppnow H, Brade H, Dürrbaum I, Dinarello CA, Kusumoto S, Rietschel ET, et al. IL-1 induction-capacity of defined lipopolysaccharide partial structures. The Journal of Immunology. 1989; 142(9): 3229-38.

      [25] 25. Seydel U, Oikawa M, Fukase K, Kusumoto S, Brandenburg K. Intrinsic conformation of lipid A is responsible for agonistic and antagonistic activity. European Journal of Biochemistry. 2000; 267(10): 3032-9.

      [26] 26. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nature immunology. 2002;3(4):354-9.

      [27] 27. Kim HM, Park BS, Kim J-I, Kim SE, Lee J, Oh SC, et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007;130(5):906-17.

      [28] 28. Huber M, Kalis C, Keck S, Jiang Z, Georgel P, Du X, et al. R-form LPS, the master key to the activation ofTLR4/MD-2-positive cells. European journal of immunology. 2006; 36(3): 701-11.

      [29] Henricson B, Perera P, Qureshi N, Takayama K, Vogel S. Rhodopseudomonas sphaeroides lipid A derivatives block in vitro induction of tumor necrosis factor and endotoxin tolerance by smooth lipopolysaccharide and monophosphoryl lipid A. Infection and immunity. 1992;60(10):4285-90.

      [30] Visintin A, Halmen KA, Latz E, Monks BG, Golenbock DT. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. The Journal of Immunology. 2005; 175(10): 6465-72.




Article ID: 20372
DOI: 10.14419/ijet.v7i4.7.20372

Copyright © 2012-2015 Science Publishing Corporation Inc. All rights reserved.